akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLCakusherstvo-10Research ArticleGYNECOLOGYГИНЕКОЛОГИЯPOSSIBILITY OF APPLICATION OF MAGNESIUM SULFATE AS A NEUROPROTECTOR IN THE DEVELOPMENT OF PREMATURE BIRTHВОЗМОЖНОСТИ ПРИМЕНЕНИЯ СУЛЬФАТА МАГНИЯ В КАЧЕСТВЕ НЕЙРОПРОТЕКТОРА ПРИ РАЗВИТИИ ПРЕЖДЕВРЕМЕННЫХ РОДОВМакаровИ. О.MakarovI. O.БоровковаЕ. И,BorovkovaE. I.Katyanikitina@mail.ruГБОУ ВПО «Первый МГМУ имени И.М. Сеченова» Минздрава РФ, МоскваРоссияGBOU VPO “First Moscow state medical university named after I.M. Sechenov” of Ministry of Healthcare of RussiaRussian Federation201327052016714144Copyright © Makarov I.O., Borovkova E.I., 20162016Макаров И.О., Боровкова Е.И.Makarov I.O., Borovkova E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/10

The paper presents the data of meta-analyses and individual randomized studies on the effectiveness of magnesium sulfate as a drug to reduce the risk of cerebral palsy in the development of premature birth.

В работе представлены данные мета-анализа и отдельных рандомизированных исследований, посвященных изучению эффективности применения сульфата магния в качестве препарата для снижения риска развития детского церебрального паралича при развитии преждевременных родов.

ПРЕЖДЕВРЕМЕННЫЕ РОДЫСУЛЬФАТ МАГНИЯДЕТСКИЙ ЦЕРЕБРАЛЬНЫЙ ПАРАЛИЧНЕЙРОПРОТЕКТИВНЫЙ ЭФФЕКТБЕРЕМЕННОСТЬpremature birthmagnesium sulphatea children's cerebral paralysisantenatal magnesium sulphateneuroprotectionpregnancyReferencesAmerican College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet. Gynecol. 2010; 115: 669.American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet. Gynecol. 2010; 115: 669.Altman D., Carroli G., Duley L. et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877.Altman D., Carroli G., Duley L. et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877.Costantine M.M., Weiner S.J., Eunice Kennedy Shriver. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. ObstetGynecol 2009; 114: 354.Costantine M.M., Weiner S.J., Eunice Kennedy Shriver. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. ObstetGynecol 2009; 114: 354.Crowther C.A., Hiller J.E., Doyle L.W. et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669.Crowther C.A., Hiller J.E., Doyle L.W. et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669.Doyle L.W., Crowther C.A., Middleton P., Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet. Gynecol. 2009; 113: 1327.Doyle L.W., Crowther C.A., Middleton P., Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet. Gynecol. 2009; 113: 1327.Doyle L.W., Crowther C.A., Middleton P. et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst. Rev. 2009; CD004661.Doyle L.W., Crowther C.A., Middleton P. et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst. Rev. 2009; CD004661.Moster D., Lie R.T., Markestad T. Long-term medical and social consequences of preterm birth. N. Engl. J. Med. 2008; 359: 262.Moster D., Lie R.T., Markestad T. Long-term medical and social consequences of preterm birth. N. Engl. J. Med. 2008; 359: 262.Marret S., Doyle L.W., Crowther C.A., Middleton P. Antenatal magnesium sulphateneuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007; 12:311.Marret S., Doyle L.W., Crowther C.A., Middleton P. Antenatal magnesium sulphateneuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007; 12:311.Marret S., Marpeau L., Follet-Bouhamed C. et al. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial. Gynecol. Obstet. Fertil. 2008; 36: 278.Marret S., Marpeau L., Follet-Bouhamed C. et al. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial. Gynecol. Obstet. Fertil. 2008; 36: 278.Nelson K.B., Grether J.K. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995; 95: 263.Nelson K.B., Grether J.K. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995; 95: 263.Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 2002; 44: 633.Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 2002; 44: 633.Pryde P.G., Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet. Gynecol. 2009; 114: 669.Pryde P.G., Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet. Gynecol. 2009; 114: 669.Rouse D.J., Hirtz D.G., Thom E. et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 2008; 359: 895.Rouse D.J., Hirtz D.G., Thom E. et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 2008; 359: 895.Saigal S., Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008; 371: 261.Saigal S., Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008; 371: 261.The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. Adelaide: The University of Adelaide. 2010.The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. Adelaide: The University of Adelaide. 2010.Yeargin-Allsopp M., Van Naarden Braun K., Doernberg N.S. et al. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008; 121: 547.Yeargin-Allsopp M., Van Naarden Braun K., Doernberg N.S. et al. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008; 121: 547.

The authors declare that there are no conflicts of interest present.